Reaction
Lichen Planus reporting signals
As of the last recalculation, Lichen Planus appears in 2,273 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is CLOBETASOL PROPIONATE OINTMENT USP, 0.05% (PRR 17.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Clobetasol Propionate Ointment Usp, 0.05% | 20 | 17.9 | 18.0 |
| Labetalol | 25 | 17.4 | 17.4 |
| Clobetasol Propionate | 18 | 16.1 | 16.1 |
| Nivolumab | 134 | 13.4 | 13.4 |
| Misoprostol | 13 | 12.3 | 12.3 |
| Botulinum Toxin Type A | 15 | 11.1 | 11.1 |
| Zonisamide | 17 | 10.6 | 10.6 |
| Nebivolol | 17 | 9.8 | 9.8 |
| Pembrolizumab | 108 | 9.8 | 9.8 |
| Mometasone | 15 | 7.5 | 7.5 |
| Candesartan Cilexetil | 21 | 7.4 | 7.4 |
| Imatinib Mesylate | 20 | 6.6 | 6.6 |
| Sumatriptan Succinate | 18 | 6.6 | 6.6 |
| Terbinafine Hydrochloride | 6 | 6.2 | 6.2 |
| Ipilimumab | 27 | 5.8 | 5.8 |
| Nebivolol Hydrochloride | 21 | 5.7 | 5.7 |
| Sumatriptan | 22 | 5.3 | 5.3 |
| Atezolizumab | 21 | 5.0 | 5.0 |
| Durvalumab | 11 | 5.0 | 5.0 |
| Imatinib | 9 | 4.7 | 4.7 |
| Bendamustine Hydrochloride | 6 | 4.6 | 4.6 |
| Ribavirin | 30 | 4.3 | 4.3 |
| Ledipasvir And Sofosbuvir | 9 | 4.3 | 4.3 |
| Pemetrexed | 10 | 4.3 | 4.3 |
| Carboplatin | 53 | 3.9 | 3.9 |
| Secukinumab | 65 | 3.8 | 3.8 |
| Ixekizumab | 15 | 3.7 | 3.7 |
| Apremilast | 57 | 3.6 | 3.6 |
| Peginterferon Alfa-2A | 20 | 3.4 | 3.4 |
| Pemetrexed Disodium | 14 | 3.4 | 3.4 |
| Denosumab | 69 | 3.2 | 3.2 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 6 | 3.0 | 3.0 |
| Bimekizumab | 7 | 3.0 | 3.0 |
| Dulaglutide | 22 | 2.3 | 2.3 |
| Alirocumab | 6 | 2.2 | 2.2 |
| Guselkumab | 8 | 2.1 | 2.1 |
| Dupilumab | 103 | 2.0 | 2.0 |
| Galcanezumab-Gnlm | 5 | 1.5 | 1.5 |